Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome by Aronson, S.J. (Sem J.) et al.
Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated
Virus Immunity in the Context of Gene Therapy
for Crigler–Najjar Syndrome
Sem J. Aronson,1 Philippe Veron,2 Fanny Collaud,2 Aure´lie Hubert,3 Virginie Delahais,2
Ge´raldine Honnet,2 Robert J. de Knegt,4 Norman Junge,5,6 Ulrich Baumann,5,6
Angelo Di Giorgio,7 Lorenzo D’Antiga,7 Virginia M. Ginocchio,8,9 Nicola Brunetti-Pierri,8,9
Philippe Labrune,3 Ulrich Beuers,1 Piter J. Bosma,1 and Federico Mingozzi2,*
1Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The
Netherlands; 2Genethon, Evry, France; 3Department of Hereditary Diseases of Hepatic Metabolism, Hoˆpital Antoine Be´cle`re, Clamart, France; 4Department of
Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands; Departments of 5Paediatric Gastroenterology and Hepatology and
6Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; 7Department of Paediatric Hepatology, Gastroenterology and
Transplantation, Papa Giovanni XXIII Hospital, Bergamo, Italy; 8Telethon Institute of Genetics & Medicine (TIGEM), Pozzuoli, Italy; 9Department of Translational
Medicine, Federico II University of Naples, Naples, Italy.
Adeno-associated virus (AAV) vector-mediated gene therapy is currently evaluated as a potential treat-
ment for Crigler–Najjar syndrome (CN) (NCT03466463). Pre-existing immunity to AAV is known to
hinder gene transfer efficacy, restricting enrollment of seropositive subjects in ongoing clinical trials. We
assessed the prevalence of anti-AAV serotype 8 (AAV8) neutralizing antibodies (NAbs) in subjects affected
by CN and investigated the impact of low NAb titers (<1:5) on liver gene transfer efficacy in an in vivo
passive immunization model. A total of 49 subjects with a confirmed molecular diagnosis of CN were
included in an international multicenter study (NCT02302690). Pre-existing NAbs against AAV8 were
detected in 30.6% (15/49) of screened patients and, in the majority of positive cases, cross-reactivity to
AAV2 and AAV5 was detected. To investigate the impact of low NAbs on AAV vector-mediated liver
transduction efficiency, adult wild-type C57BL/6 mice were passively immunized with pooled human
donor-derived immunoglobulins to achieve titers of up to 1:3.16. After immunization, animals were in-
jected with different AAV8 vector preparations. Hepatic vector gene copy number was unaffected by low
anti-AAV8 NAb titers when column-purified AAV vector batches containing both full and empty capsids
were used. In summary, although pre-existing anti-AAV8 immunity can be found in about a third of
subjects affected by CN, low anti-AAV8 NAb titers are less likely to affect liver transduction efficiency
when using AAV vector preparations manufactured to contain both full and empty capsids. These findings
have implications for the design of liver gene transfer clinical trials and for the definition of inclusion
criteria related to seropositivity of potential participants.
Keywords: Crigler–Najjar syndrome, UGT1A1, unconjugated hyperbilirubinemia, AAV gene therapy,
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INTRODUCTION
CRIGLER–NAJJAR SYNDROME (CN) is an ultrarare au-
tosomal recessive inborn error of metabolism
characterized by severe unconjugated hyperbilir-
ubinemia, due to marked reduction or complete
lack of uridine diphosphoglucuronosyl transferase
1A1 (UGT1A1) in the liver.1,2 This enzyme defi-
ciency restricts glucuronidation and subsequent
elimination of unconjugated bilirubin (UCB). Ac-
cumulation of neurotoxic bilirubin can cause
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encephalopathy, also known as kernicterus, that
leads to severe and irreversible disability or death
without appropriate treatment.3 Severely affected
patients depend on phototherapy for up to 14 h a
day to convert UCB into photoisomers in the skin
and underlying capillaries, which can be readily
excreted through bile or urine.4,5 Currently, liver
transplantation is the only curative treatment for
CN and becomes inevitable at some point in life due
to the burden of phototherapy and the long-term
complications associated with CN.4,6 However, li-
ver transplantation is associated with procedure-
related complications. Furthermore, the burden
and risks related to lifelong immunosuppression
and limited availability of donor livers underscore
the need to develop novel therapeutic approaches
for CN.
Adeno-associated virus (AAV) vector-mediated
gene therapy is a potentially curative approach for
inherited monogenic disorders and was success-
fully translated to clinical applications in the past
decade.7–14 Pivotal studies of gene transfer for he-
mophilia A (NCT03392974) and B (NCT03587116,
NCT03569891) are ongoing based on earlier clini-
cal data supporting the safety of liver gene transfer
with AAV vectors and on promising preliminary
efficacy data on long-term reduction of bleeding
episodes.10–12 Preclinical studies in the relevant
models of CN showed complete and sustained cor-
rection of plasma bilirubin levels after a single
intravenous administration of an AAV serotype
8 (AAV8) vector encoding for the human UGT1A1
gene (AAV8–hUGT1A1).15–17 Efforts to optimize and
develop the vector for clinical application have
resulted in a lead candidate investigational vec-
tor that is currently under clinical evaluation
(NCT03466463).18,19
Although AAV-mediated gene therapy holds
great promise for treatment of CN, not all patients
are eligible candidates for this novel approach.
Anti-AAV immunity, which arises after exposure
to the wild-type virus, can compromise success-
ful gene transfer after systemic administration of
recombinant AAV (rAAV) vectors.20,21 The neutral-
izing antibodies (NAbs) that impair the transduction
are only a part of the total anti-AAV antibodies.22,23
The prevalence of NAbs toward different AAV
subtypes reported in the literature is variable, but
a high prevalence is found for AAV2 (*30–60%)
compared with other serotypes in the general
population.24–26 Reports about seroprevalence of
AAV in patients with CN are currently lacking.
The influence of NAbs on the outcome of AAV
vector-mediated gene delivery is not fully eluci-
dated. Earlier observations already showed that
even low anti-AAV NAbs decrease vector trans-
duction efficiency27,28; however, follow-up studies
indicate that low NAb titers (<1:5) can, at least
partially, be overcome by increasing the adminis-
tered dose of AAV.29,30 Besides the NAb titer and the
AAV vector dose, also the formulation of the AAV
vector preparation (e.g., full to empty capsid ratio)
was identified as a modulating factor. Accordingly,
increasing the relative amount of empty capsids in
the AAV preparation, either deliberately31 or as a
consequence of the vector production protocol,32 re-
duces the negative effect of NAbs on transduction
efficiency. Based on these findings, here we further
investigated the relevance of low NAb titers on he-
patic transduction efficiency by AAV vectors to de-
termine whether borderline seropositive subjects
could also be eligible for liver-directed gene therapy.
To this aim, we first assessed the prevalence of
anti-AAV8 NAbs in a cohort of 49 CN patients and
then investigated the relevance of low NAb titers
on gene transfer efficacy of different AAV vector
preparations in a passively immunized murine
model of gene transfer.
MATERIALS AND METHODS
Patient cohort study design
Patients with a genetically confirmed diagnosis
of CN who have not received a liver transplant
were included in an observational international
multicenter study (NCT02302690). At time of in-
clusion, a serum sample was collected and anti-
AAV immunity was assessed centrally at Gene-
thon’s laboratory (Evry). This study was reviewed
and approved by the independent ethics commit-
tees of all five participating sites (Hoˆpital Antoine
Be´cle`re, Clamart, France; Academic Medical Cen-
ter, Amsterdam, the Netherlands; Azienda Ospe-
daliera Papa Giovanni XXIII, Bergamo, Italy;
Federico II University Hospital of Naples, Naples,
Italy; Hannover Medical School, Hannover, Ger-
many) and was carried out in compliance with the
Good Clinical Practice guidelines and according to
the principles of the declaration of Helsinki. All
participants gave written informed consent or, in
the case of children, assent and parental consent.
Production and characterization
of AAV vectors
AAV vectors were produced following two dif-
ferent manufacturing processes in adherent and
in suspension HEK293 cells, as previously de-
scribed.19 In brief, adherent HEK293 cells grown
in roller bottles were transfected with the three
plasmids containing the adenovirus helper proteins,
the AAV Rep and Cap genes, and the ITR-flanked
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transgene expression cassette. Seventy-two hours
after transfection, cells were harvested, lysed by
sonication, and treated with Benzonase (Merck-
Millipore, Darmstadt, Germany). Vectors were then
purified using two successive ultracentrifugation
rounds in cesium chloride density gradients. Full
capsids were collected, the final product was for-
mulated in sterile phosphate-buffered saline (PBS)
containing 0.001% of Pluronic (Sigma-Aldrich, Saint
Louis, MO), and stored at -80C.
For suspension HEK production, AAV vectors
were produced in bioreactors by the adenovirus-
free transient transfection method. HEK293 cells
were transfected with polyethyleneimine (PEI-
pro, Polyplus, France) with the same three plas-
mids used in adherent HEK293 cells. Vectors were
purified by a single chromatography column based
on AVB Sepharose immunoaffinity (GE Health-
care, Buc, France) before concentration by tan-
gential flow filtration. Purified particles were
formulated in Ringer’s lactate solution containing
0.001% Pluronic (F68), vialed and stored at -80C.
Vector titers were determined by quantitative
PCR (qPCR). Specific probe and primers used for
amplification and detection of viral DNA were
forward 5¢-GGCGGGCGACTCAGATC-3¢, reverse
5¢-GGGAGGCTGCTGGTGAATATT-3¢, probe 5¢-
AGCCCCTGTTTGCTCCTCCGATAACTG-3¢. Vector
titers are expressed in viral genomes per milliliter
(vg/mL) and are shown as average of three titration
runs.
Anti-AAV NAb titer determination
For determination of anti-AAV8 NAb titer in
serum, an in vitro reporter system was used as
previously described.33 In brief, 96-well plates were
seeded with 2· 104 2V6.11 cells/well and incubated
in DMEM with 10% fetal calf serum at 37C and 5%
CO2 for 24 h in the presence of ponasterone A (Life
Technologies, Carlsbad, CA). Recombinant AAV8-
CMV-luciferase (AAV8-CMV-Luc) was diluted in
serum-free DMEM (Life Technologies) and incu-
bated with threefold serial dilutions (1:1–1:3,160)
of the serum samples, and then incubated for 1 h at
37C. Subsequently, the serum–vector mixtures
were added to the 2V6.11 cells, and after 24 h, cells
were lysed with the Bright Glo system (Promega,
Madison, WI) and the luciferase activity was
measured on a luminometer (ENSPIRE; Perkin
Elmer, Waltham, MA). The NAb titer was reported
as the highest serum dilution that inhibited AAV
transduction by ‡50% compared with the control
without serum (100% transduction). Anti-AAV8
NAb titer was assessed in two independent ex-
periments for all subjects. Any sample with a
detectable anti-AAV8 NAb titer (‡1:1) in both ex-
periments was determined as seropositive. Also
NAb cross-reactivity to AAV5 and AAV2 was as-
sessed using this in vitro reporter method using
AAV5-CMV-Luc and AAV2-CMV-Luc in samples
that were positive for anti-AAV8 NAbs.
IgM/IgG analysis for AAV8, AAV5, and AAV2
In addition to NAb titer analysis, we assessed
the prevalence of both total IgG and IgM binding
antibodies to AAV using an enzyme-linked immu-
nosorbent assay as previously described.24 In brief,
96-well Nunc polysorp immunoplates (Dutscher,
Paris, France) were coated with AAV particles to a
final concentration of 1 lg/mL. A standard curve
made of purified human IgG or IgM (Interchim,
Montluc¸on, France) was added directly to the
plates. Plates were coated overnight at 4C. The
next day, after blocking the plates, serum samples
were added at dilution of 1:10 and 1:100 in dupli-
cate and incubated overnight at 4C. Monoclonal
antihuman IgG or IgM HRP-conjugated (Southern
Biotech, Birmingham, AL) was added to the plates.
The enzymatic reaction was developed with sub-
strate solution (3,3¢,5,5¢-tetramethylbenzidine
from Becton Dickinson, Franklin Lakes, NJ). The
reaction was stopped with H2SO4 3 M solution
and optical density measurements were done at
450 nm using a microplate reader (ENSPIRE;
Perkin Elmer). Anti-AAV antibody concentration
was determined against the IgG or IgM-specific
standard curve.
Animal study design
Adult male C57BL/6 mice received a single
intraperitoneal administration of pooled donor-
derived human intravenous immunoglobulin
(IVIg; Grifols, Paris, France) at a dose of 0.5 mg
(n = 12) or 1.5 mg (n =12) or PBS control (n =12)
at day 0. After 24 h, animals received either the
AAV8–hUGT1A1 vector produced by triple trans-
fection of adherent HEK293 cells (ADH) or
HEK293 cells cultured in suspension (SUSP) at a
dose of 2E12 vg/kg (n = 6 per group). At day 22, mice
were sacrificed, blood was sampled, and liver tissue
was snap frozen in liquid nitrogen and stored at
-80C for further analysis. All animal experiments
were performed in accordance with the European
Directive 2010/63/EU and with approval of the lo-
cal Institutional Animal Care and Use Committee
(ref.: 2014-009B). Vector genome copy number
(VGCN) in liver was determined by qPCR with the
same set of primers and probes described for vector
titering.
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Statistical analysis
Results are presented as frequency with percent-
age, mean with standard deviation, or median with
25–75%. Statistical methods used for data analysis
are specified in the results section and figure legends.
A p-value <0.05 was considered statistically signifi-
cant. Analyses were performed using SPSS (version
24.0) and GraphPad Prism Software (version 7.0).
RESULTS
Baseline characteristics of participants
Between November 2014 and November 2016, a
total of 49 subjects affected with CN were enrolled
into the observational study. Gender was distrib-
uted equally (53.1% female). The median age of
participants at inclusion was 20 years (5–26). By
medical history, six subjects underwent cholecys-
tectomy and eight subjects other surgical proce-
dures (subtotal thyroidectomy, hysterectomy,
mastectomy, or cesarean section). Genetic confir-
mation of the diagnosis of CN was available in all
participants, with the highest allele frequency of
c.1220delA (p.K407X) in 16.3% of subjects. All par-
ticipants were receiving treatment to reduce serum
UCB at time of inclusion and during follow-up.
Treatment comprised either phenobarbital,
phototherapy, or a combination of both. Among a
total of 42 participants receiving phototherapy, 20
of them used it in combination with phenobarbital
(Fig. 1). Subjects affected by a milder form of CN
were not receiving any phototherapy. Thirty-one
participants required ‡8 h of phototherapy expo-
sure per day, representing 63.3% of the total co-
hort. The mean serum total bilirubin at inclusion
was 303.4 –108.9 lmol/L. A summary of the co-
hort’s baseline characteristics is given in Table 1.
Prevalence of anti-AAV8 NAbs and serotype
cross-reactivity
To assess what percentage of the study popula-
tion was potentially eligible for inclusion in AAV
gene transfer trials, a serum sample was collected
from each participant at the time of inclusion. Pre-
existing anti-AAV8 NAbs were detected in 15 of the
49 screened participants (30.6%), with NAb titers
ranging from 1:1 to 1:1,000 (Table 2). Results from
two independent experiments show minor devia-
tions of serum anti-AAV8 NAb titers in four sub-
jects (not shown). As previously described,31 the
vast majority of AAV8 seropositive subjects have
titers £1:100, and only three subjects presented
titers of 1:1,000 (Table 2). Individuals seropositive
for anti-AAV8 NAbs also presented anti-AAV5
NAb titers in serum, except for three subjects, al-
though lower titers than those against AAV8 were
measured (Table 2). As expected, based on the high
Figure 1. Management of CN in the selected population. Results are re-
ported as percentage of total (n = 49). CN, Crigler–Najjar syndrome.
Table 1. Baseline characteristics of Crigler–Najjar subjects
N 49
Female 26 (53.1%)
Age (years) 20 (5–26)
Allele frequency
1220DelA 16 (16.3%)
1489DelG 10 (10.2%)
A(TA)7TAA 8 (8.2%)
1381T>C 6 (6.1%)
1070A>G 3 (3.1%)
Other 55 (56.1%)
Phototherapy
None 7 (14.3%)
<8 h 11 (22.4%)
>8 h 31 (63.3%)
Total bilirubin (lmol/L) 303.4– 108.9
Direct bilirubin (lmol/L) 19.0 – 12.6
Data are presented as frequency (%), median (25–75&), or mean– SD
Table 2. Cross-reactivity of anti-adeno-associated virus
neutralizing antibodies
Gender NAb AAV8 NAb AAV5 NAb AAV2
Female 1:1,000 1:316 >1:3,160
Female 1:1,000 1:316 >1:3,160
Female 1:1,000 1:1,000 >1:3,160
Female 1:100 1:100 1:316
Female 1:100 1:100 1:3,160
Female 1:100 1:31.6 1:1,000
Female 1:100 1:3.16 1:316
Female 1:100 1:3.16 1:316
Male 1:31.6 1:1 1:31.6
Male 1:10 1:3.16 1:316
Female 1:10 1:3.16 1:100
Male 1:3.16 1:1 1:10
Male 1:1 <1:1 1:31.6
Female 1:1 <1:1 1:31.6
Male 1:1 <1:1 1:3.16
In 15 of 49 participants, anti-AAV8 NAbs were detected and most of them
showed cross-reactivity to AAV5 and AAV2. Serum anti-AAV8 NAb titers
are shown for all 15 seropositive patients. Cross-reactivity against AAV5
and AAV2 was assessed. NAb titers are expressed as the highest serum
dilution that inhibited AAV transduction by ‡50% compared with the control
without serum.
AAV, adeno-associated virus; NAbs, neutralizing antibodies.
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seroprevalence of AAV2 in healthy donors,24 all
anti-AAV8 NAb-positive subjects showed anti-
AAV2 NAb titers in serum, which were generally
higher than those against AAV8 (Table 2). Notably,
subjects with pre-existing anti-AAV8 NAbs were
older at time of sampling than seronegative pa-
tients (p=0.011; Fig. 2).
Thus, based on these results, screening for
anti-AAV NAb titers to AAV8, AAV5, and AAV2
in subjects affected by CN showed both seropre-
valence and antibody titers similar to those previ-
ously documented in healthy donors.
Correlation between anti-AAV NAb titers
and total IgG binding antibodies
Anti-AAV NAb titers are often directly corre-
lated to the concentration of circulating anti-AAV
IgG,34 although in some cases low anti-AAV IgG
titers are found not to be neutralizing.23 To evaluate
the correlation between NAb titers and binding an-
tibodies, total IgG antibody concentration to AAV8,
AAV5, and AAV2 was determined by ELISA in all
serum samples that were identified as seropositive
for anti-AAV8 NAbs (n=15/49). Within the sample
set tested, a generally good correlation between NAb
and IgG levels was found (Fig. 3A, C, E). Anti-AAV8
NAb titer versus total IgG antibody concentration
showed the strongest correlation (R2=0.88) (Fig. 3A),
with less strong correlations for AAV5 (R2=0.70) and
AAV2 (R2=0.56) (Fig. 3C, E, respectively).
As NAb titers can also be influenced by IgM re-
sponses originated by recent exposure to AAV, total
IgM antibody concentration against AAV8, AAV5,
and AAV2 was also determined by ELISA. In all
subjects tested (n =49) and for all serotypes, IgM
levels were found to be below the limit of detection
(Fig. 3B, D, F). These results confirm that NAb ti-
ters correlate with IgG levels across serotypes and
that IgM is only rarely found.
Effect of low NAb titers on liver transfer
efficiency and relationship with AAV vector
purification method
AAV vectors can be manufactured according to
different protocols35 and, mainly depending on the
downstream purification method, a mixture of
variable proportions of empty and full capsids can be
found in the final product. As empty capsids present
in AAV vector preparation can greatly affect the
outcome of liver gene transfer,31 we next tested the
impact of low-titer NAbs on murine liver transfer
efficiency with different preparations of AAV8–
hUGT1A1 vector. AAV8–hUGT1A1 vectors made
by transfecting HEK293 cells grown in adherent
cultures (AAV8 ADH) and purified by double CsCl
gradient35 were compared with preparations of the
same vector construct using suspension HEK293
cell cultures (AAV8 SUSP) and column purifica-
tion.19 Although AAV8 ADH had virtually no empty
capsid in the final purified product, AAV8 SUSP
had a ratio of about 1:5 full to empty capsids.19
The impact of low anti-AAV8 NAb titers on he-
patic gene transfer efficacy after systemic delivery
of rAAV8–hUGT1A1 was assessed by measuring
VGCNs in liver tissue after transduction of pas-
sively immunized mice (Fig. 4A). To minimize the
potential issue of differences in infectivity of the
vector preparations made with the two methods, a
PBS-treated control group was included for both
animals infused with adherent and suspension
preparations of the AAV8–hUGT1A1 vector. One
day after intraperitoneal administration of pooled
human IVIg in C57BL/6 mice, low titers of anti-AAV8
NAbs up to 1:3 were measured in serum of these
animals (Fig. 4B). Animals randomly received one of
the two vector preparations through tail vein injec-
tion 24 h after passive immunization. VGCN in liver
tissue, assessed 3 weeks after vector administration
by qPCR, was decreased by 60% ( p < 0.01) in ani-
mals that were passively immunized with the
highest dose of IVIg (1.5 mg) before the AAV8 ADH
vector injection (Fig. 4C). Conversely, no decrease
in VGCN was detected in animals receiving the
AAV8 SUSP vector (Fig. 4D), suggesting that
vector preparations of AAV8–hUGT1A1 contain-
ing empty capsids have a more efficient trans-
duction potential in the presence of NAbs.
Together, these results indicate that even
seemingly small differences in vector manufactur-
ing can potentially affect the outcome of liver gene
transfer.
Figure 2. Subjects with pre-existing anti-AAV8 NAbs were older than
seronegative subjects. The age in years at time of NAb determination of
subjects with NAb titer >1:1 (positive, n = 15) versus NAb titer £1:1 (nega-
tive, n = 34). Two-tailed t-test was used to compare groups (*p< 0.05).
NAbs, neutralizing antibodies.
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DISCUSSION
AAV-mediated gene therapy for CN has been
established in animal models supporting efforts
toward translation into clinical trials. Currently,
not all individuals affected by severe CN are eligi-
ble candidates for this novel approach due to pre-
existing immunity to AAV vectors. In this study,
we assessed the prevalence of both anti-AAV NAbs
and total immunoglobulin G (IgG) binding anti-
body concentrations in a cohort of 49 CN patients.
Since we identified subjects who were borderline
seropositive, with an anti-AAV8 NAb titer <1:5, we
also assessed the relevance of low NAb titers on
gene transfer efficacy in a murine model.
At time of inclusion, NAbs against AAV8 were
detected with a frequency that was comparable
with previous reports.24,25 In addition, we observed
a broad cross-reactivity with both relatively con-
served (AAV2) and distant (AAV5) serotypes.36 A
broad cross-reactivity of NAbs toward different
AAV subtypes has been described previously and is
likely the result of the overall high amino acid se-
quence and structure homologies across AAV se-
rotypes.21 We observed a higher cross-reactivity
between AAV8 and AAV2 than between AAV8 and
AAV5. This is likely the result of closer structural
homology between AAV8 and AAV2 than between
AAV8 and AAV5, as previously described.24 An-
Figure 3. Correlation between anti-AAV8 NAb titers and total IgG and IgM to AAV serotypes 8, 5, and 2 in subjects affected by CN. (A) Anti-AAV8 NAb titer
versus total IgG binding antibodies to AAV8 measured in seropositive subjects (n= 15). (B) IgM binding antibodies to AAV8 (n = 49). (C) Anti-AAV5 NAb titer
versus total IgG binding antibodies to AAV5. (D) IgM binding antibodies to AAV5. (E) Anti-AAV2 NAb titer versus total IgG binding antibodies to AAV2. (F) IgM
binding antibodies to AAV2. NAb titers are reported as reciprocal dilutions (1:x). The dotted line represents the limit of quantification for IgM.
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other finding in this study is that older subjects
appeared to have a higher chance to be seroposi-
tive. Since pre-existing anti-AAV immunity arises
after exposure to the naturally occurring virus, this
finding is not surprising and is aligned with pre-
viously published reports.37,38 The lack of detection
of IgM-positive subjects may be dependent on spo-
radic exposure to the wild-type virus and on short-
term persistence of IgM that are typically produced
over a brief period of time before isotype switching.
In addition, longitudinal studies in humans showed
that anti-AAV antibody titers tend to be very stable
over time,39 suggesting that multiple infections with
wild-type AAV are uncommon, and so the appear-
ance of IgM. As we previously described,34 also in
this study we identified a strong correlation between
NAb titer and total IgG antibody concentration.
By investigating the relevance of low anti-AAV8
NAb titers to liver gene transfer efficiency after
systemic delivery of AAV8–hUGT1A1 in passively
immunized mice, we identified a significant differ-
ence between the AAV vector preparations based
on empty capsid content. In particular, in an effort
to initiate a phase I/II trial in individuals affected
by CN (NCT03466463), we developed and opti-
mized an AAV8–hUGT1A1 vector to correct
the CN phenotype in murine models,18 and scaled
up manufacturing to provide adequate amounts
of clinical-grade vector.19 An important step in
this process was changing the production method
from transient triple transfection of adherent
HEK293 cells to transfection of HEK293 cells in
suspension grown in high-volume bioreactors.40
The production process using cell culture in
suspension is dependent on a column-based affinity
purification technique that, in contrast to the orig-
inal adherent cell method, does not completely
eliminate the empty particles from the final drug
product. The presence of empty capsids in the AAV8
SUSP preparations does not seem to influence liver
transduction efficacy.19 However, based on previ-
ous reports on empty capsids acting as decoys for
NAbs,31 here we sought to establish the tolerance of
AAV8 SUSP vectors to low levels of NAbs and pro-
vide preliminary evidence of the impact of changes
in AAV vector manufacturing on the impact of gene
transfer in liver. Our observation that VGCN in li-
ver of passively immunized mice is not reduced af-
ter administration of AAV8 SUSP is in line with
the hypothesis that efficacy of gene transfer can be
maximized by a mixture of empty and full capsids.
Whether anti-AAV NAb titers can be overcome in
Figure 4. VGCNs in liver of passively immunized mice after receiving AAV vector preparations obtained with different manufacturing methods. (A) Ex-
perimental design, indicating passive immunization regimens with IVIg at day 0 followed by the administration of two different AAV vector preparations at day
1; a total of six experimental groups with n= 6 per group were included in the study and all animals were sacrificed at day 22 postvector infusion. (B) Anti-
AAV8 NAb titer (reciprocal dilution, 1:x) measured by an in vitro reporter assay, 24 h after the three immunization regimens. (C, D) VGCN assessed by qPCR in
liver tissue at the time of sacrifice (d22) in animals receiving vectors made by triple transfection of adherent HEK293 cells (AAV8 ADH) or HEK293 cells cultured
in suspension (AAV8 SUSP). Results are expressed as fold relative to PBS-treated animals. Statistical significance was determined with one-way ANOVA with
Bonferroni post-test comparison of all treatment groups (**p < 0.01). Data are represented as mean– standard deviation. IVIg, intravenous immunoglobulin;
PBS, phosphate-buffered saline; qPCR, quantitative PCR; VGCN, vector genome copy number.
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human subjects by modulating the empty-to-full
capsid ratio warrants further investigation, al-
though evidence that this approach is clinically
feasible comes from earlier studies of gene transfer
for hemophilia B.11 However, establishing the op-
timal full-to-empty capsid ratio and maximal NAb
titer at which AAV vector transduction efficacy re-
mains unaffected is challenging, as the total vector
dose also plays a role in overcoming the anti-AAV
NAbs. Furthermore, it is likely that this approach is
only valuable as a rescue measure for individuals
with low NAb titers, and other strategies will be re-
quired to circumvent the negative effects of anti-AAV
NAbs in high-titer seropositive subjects. A potential
disadvantage of administrating empty capsids pres-
ent as contaminants of vector preparations is that
this increases the total capsid dose, which may result
in the activation of capsid-specific T cells, potentially
limiting the duration of transgene expression.20,41
Alternative approaches to overcome pre-existing
AAV immunity have extensively been reviewed.21,42
One particularly promising approach, aimed at re-
ducing anti-AAV antibodies from the circulation
before vector administration, is plasmapheresis.43,44
Extracorporeal plasma exchange techniques are
routinely used in the clinical setting to remove
undesired immunoglobulins from the systemic cir-
culation. In the setting of humoral immunity to AAV,
it has been demonstrated that sequential plasma-
pheresis cycles can lead to a substantial reduction
and even depletion of anti-AAV NAbs.44 Further-
more, studies in seropositive nonhuman primates
showed that removing NAbs by plasmapheresis
preserved transgene expression at levels compara-
ble with those of treated seronegative animals after
AAV vector-mediated gene transfer.43 Plasmapher-
esis techniques are readily available for clinical use
and are generally regarded as a safe medical proce-
dure, rendering this method attractive to precede
AAV vector administration in anti-AAV seropositive
patients. However, one caveat related to plasma-
pheresis is that the extremely high NAb titers trig-
gered by vector administration are likely to render
the technology unuseful for vector readministration.
In this setting, pharmacological blockade of antibody
formation may be a better option.45
In summary, pre-existing anti-AAV immunity
was found in *30% of Crigler–Najjar subjects,
which currently restricts enrollment of a signifi-
cant proportion of patients in ongoing gene therapy
trials. Although the development of strategies to
circumvent the negative effects of NAbs on AAV-
mediated transduction efficacy is an urgent task
for the field, this study showed that low NAb titers,
found in the context of natural immunity to AAV,
can be overcome by administrating AAV prepara-
tions containing both full and empty capsids, of-
fering a potential approach to treat a subgroup of
borderline seropositive patients.
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